GRAIL Inc. (GRAL)
NASDAQ
Healthcare
Biotechnology
$72.62
▲ +0.92%
Market Cap
$3.12B
Sector
Healthcare
Industry
Biotechnology
Beta
3.22
52-Wk Range
29.95-118.84
CEO
Joshua J. Ofman
Country
US
Currency
USD
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-…
Open full interactive analysis & DCF →